PLX-200
PLX-200-002
Phase 3 small_molecule active
Quick answer
PLX-200 for Juvenile Neuronal Ceroid Lipofuscinosis is a Phase 3 program (small_molecule) at Polaryx Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Polaryx Therapeutics
- Indication
- Juvenile Neuronal Ceroid Lipofuscinosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active